Monte Rosa Therapeutics, Inc. Insider Trading

GLUE

Last 12 months

Insiders sold $4.11M and bought nothing on the open market.

54% of the selling was scheduled in advance under 10b5-1 plans. Principal Accounting Officer Edmund Dunn sold 465K on Mar 2, 53% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−$4.11M

0 buys · 31 sales

Under a 10b5-1 plan

54%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Mar 2025

Mar 24, 2025

Get an email when GLUE's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 5	Matthew Bowen Principal Accounting Officer	SoldNo plan	13	$10.56	$137	<0.1%	Form 4
Jul 16	Markus Warmuth President & CEO	SoldNo plan	9,500	$23.18	220K	1.6%	Form 4
Jul 15	Jennifer Champoux Chief Operating Officer	Sold10b5-1 plan	4,351	$23.38	102K	6.5%	Form 4
Jul 6	Sharon Townson Chief Scientific Officer	Sold10b5-1 plan 2 parts	6,000	$23.31 average	140K	8.1%	Form 4
Jun 30	Filip Janku Chief Medical Officer	Sold10b5-1 plan	5,407	$24.50	132K	8.2%	Form 4
Jun 29	Filip Janku Chief Medical Officer	Sold10b5-1 plan	6,000	$22.95	138K	9.1%	Form 4
Jun 29	Anthony M. Manning Director	SoldNo plan	10,000	$23.11	231K	100%	Form 4
Jun 23 – 24	Filip Janku Chief Medical Officer	Sold10b5-1 plan 2 parts	41,845	$21.08 average	882K	41%	Form 4
Jun 23	Sharon Townson Chief Scientific Officer	Sold10b5-1 plan	3,000	$20.00	60K	4.2%	Form 4
Jun 23	Jennifer Champoux Chief Operating Officer	Sold10b5-1 plan	2,175	$20.00	44K	3.4%	Form 4
Jun 17	Jennifer Champoux Chief Operating Officer	Sold10b5-1 plan	2,176	$19.00	41K	3.4%	Form 4
Jun 17	Sharon Townson Chief Scientific Officer	Sold10b5-1 plan	3,000	$19.00	57K	4.2%	Form 4
Jun 1	Markus Warmuth President & CEO	Sold10b5-1 plan 2 parts	5,466	$19.44 average	106K	0.9%	Form 4
May 29	Sharon Townson Chief Scientific Officer	Sold10b5-1 plan	6,000	$19.87	119K	8.1%	Form 4
May 27	Jennifer Champoux Chief Operating Officer	Sold10b5-1 plan	2,175	$20.00	44K	3.4%	Form 4
May 22	Jennifer Champoux Chief Operating Officer	Sold10b5-1 plan	2,176	$19.00	41K	3.4%	Form 4
May 21	Anthony M. Manning Director	SoldNo plan	10,000	$18.01	180K	100%	Form 4
May 1	Markus Warmuth President & CEO	Sold10b5-1 plan	5,467	$18.92	103K	0.9%	Form 4
Apr 14	Markus Warmuth President & CEO	SoldNo plan	8,000	$17.64	141K	1.3%	Form 4
Apr 9	Philip Nickson Chief Business & Legal Officer	SoldNo plan	5,845	$17.69	103K	9.6%	Form 4
Mar 4	Edmund Dunn Principal Accounting Officer	SoldNo plan	139	$17.96	2K	0.6%	Form 4
Mar 2	Markus Warmuth President & CEO	Sold10b5-1 plan	5,466	$17.92	98K	0.9%	Form 4
Feb 27 – Mar 2	Edmund Dunn Principal Accounting Officer	SoldNo plan 2 parts	25,700	$18.09 average	465K	53%	Form 4
Feb 23	Filip Janku Chief Medical Officer	SoldNo plan	9,189	$19.50	179K	12%	Form 4
Jan 7	Markus Warmuth President & CEO	Sold10b5-1 plan 3 parts	5,466	$23.48 average	128K	0.9%	Form 4
Jan 5	Philip Nickson Chief Business & Legal Officer	SoldNo plan	3,155	$15.17	48K	4.9%	Form 4
Jan 5	Jennifer Champoux Chief Operating Officer	SoldNo plan	2,629	$15.17	40K	4.0%	Form 4
Jan 5	Edmund Dunn Principal Accounting Officer	SoldNo plan	1,039	$15.17	16K	4.4%	Form 4
Jan 5	Markus Warmuth President & CEO	SoldNo plan	10,135	$15.17	154K	1.6%	Form 4
Jan 5	Filip Janku Chief Medical Officer	SoldNo plan	3,155	$15.17	48K	4.0%	Form 4
Jan 5	Sharon Townson Chief Scientific Officer	SoldNo plan	3,155	$15.17	48K	4.4%	Form 4
Jun 3, 2025	Edmund Dunn Principal Accounting Officer	SoldNo plan	2,062	$4.45	9K	8.0%	Form 4
Mar 24, 2025	Chandra P. Leo Director	Bought	10,000	$5.84	58K	New	Form 4

Oct 5No plan
Matthew Bowen
Principal Accounting Officer · sold 13 at $10.56
$137
<0.1% of stake
Jul 16No plan
Markus Warmuth
President & CEO · sold 9,500 at $23.18
220K
1.6% of stake
Jul 1510b5-1 plan
Jennifer Champoux
Chief Operating Officer · sold 4,351 at $23.38
102K
6.5% of stake
Jul 610b5-1 plan
Sharon Townson
Chief Scientific Officer · sold 6,000 at avg $23.31
140K
8.1% of stake
Jun 3010b5-1 plan
Filip Janku
Chief Medical Officer · sold 5,407 at $24.50
132K
8.2% of stake
Jun 2910b5-1 plan
Filip Janku
Chief Medical Officer · sold 6,000 at $22.95
138K
9.1% of stake
Jun 29No plan
Anthony M. Manning
Director · sold 10,000 at $23.11
231K
100% of stake
Jun 23 – 2410b5-1 plan
Filip Janku
Chief Medical Officer · sold 41,845 at avg $21.08
882K
41% of stake
Jun 2310b5-1 plan
Sharon Townson
Chief Scientific Officer · sold 3,000 at $20.00
60K
4.2% of stake
Jun 2310b5-1 plan
Jennifer Champoux
Chief Operating Officer · sold 2,175 at $20.00
44K
3.4% of stake
Jun 1710b5-1 plan
Jennifer Champoux
Chief Operating Officer · sold 2,176 at $19.00
41K
3.4% of stake
Jun 1710b5-1 plan
Sharon Townson
Chief Scientific Officer · sold 3,000 at $19.00
57K
4.2% of stake
Jun 110b5-1 plan
Markus Warmuth
President & CEO · sold 5,466 at avg $19.44
106K
0.9% of stake
May 2910b5-1 plan
Sharon Townson
Chief Scientific Officer · sold 6,000 at $19.87
119K
8.1% of stake
May 2710b5-1 plan
Jennifer Champoux
Chief Operating Officer · sold 2,175 at $20.00
44K
3.4% of stake
May 2210b5-1 plan
Jennifer Champoux
Chief Operating Officer · sold 2,176 at $19.00
41K
3.4% of stake
May 21No plan
Anthony M. Manning
Director · sold 10,000 at $18.01
180K
100% of stake
May 110b5-1 plan
Markus Warmuth
President & CEO · sold 5,467 at $18.92
103K
0.9% of stake
Apr 14No plan
Markus Warmuth
President & CEO · sold 8,000 at $17.64
141K
1.3% of stake
Apr 9No plan
Philip Nickson
Chief Business & Legal Officer · sold 5,845 at $17.69
103K
9.6% of stake
Mar 4No plan
Edmund Dunn
Principal Accounting Officer · sold 139 at $17.96
2K
0.6% of stake
Mar 210b5-1 plan
Markus Warmuth
President & CEO · sold 5,466 at $17.92
98K
0.9% of stake
Feb 27 – Mar 2No plan
Edmund Dunn
Principal Accounting Officer · sold 25,700 at avg $18.09
465K
53% of stake
Feb 23No plan
Filip Janku
Chief Medical Officer · sold 9,189 at $19.50
179K
12% of stake
Jan 710b5-1 plan
Markus Warmuth
President & CEO · sold 5,466 at avg $23.48
128K
0.9% of stake
Jan 5No plan
Philip Nickson
Chief Business & Legal Officer · sold 3,155 at $15.17
48K
4.9% of stake
Jan 5No plan
Jennifer Champoux
Chief Operating Officer · sold 2,629 at $15.17
40K
4.0% of stake
Jan 5No plan
Edmund Dunn
Principal Accounting Officer · sold 1,039 at $15.17
16K
4.4% of stake
Jan 5No plan
Markus Warmuth
President & CEO · sold 10,135 at $15.17
154K
1.6% of stake
Jan 5No plan
Filip Janku
Chief Medical Officer · sold 3,155 at $15.17
48K
4.0% of stake
Jan 5No plan
Sharon Townson
Chief Scientific Officer · sold 3,155 at $15.17
48K
4.4% of stake
Jun 3, 2025No plan
Edmund Dunn
Principal Accounting Officer · sold 2,062 at $4.45
9K
8.0% of stake
Mar 24, 2025
Chandra P. Leo
Director · bought 10,000 at $5.84
58K
New position

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GLUE, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with GLUE

CompareIntrinsic value

SCLXScilex Holding Company

$1.83-1.08%0

ATRAAtara Biotherapeutics, Inc.

$8.37+2.07%15

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

MGXMetagenomi, Inc.

$0.79+3.95%10

ACLXArcellx, Inc.

No recent price10

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

VYGRVoyager Therapeutics Inc.

$1.87+2.19%10

Held by ETFs

GLUE is in 38 US ETFs. The largest of them, with GLUE's weight in each:

Spot a number that looks wrong? Check it in GLUE's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GLUE

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.